Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to buy Allergan Plc’s generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission on July 26.
The $40.5 billion deal was announced in July 2015 and further solidifies Teva’s position as the world’s leading manufacturer of generics while freeing Allergan to focus on branded drugs.
Teva expects to close the transaction next week and has said that the combined company will have about 338 product registrations and will hold the leading position as the initial market entrant for around 115 pending U.S. generic drug applications.
Full Content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Turkish Antitrust Authority Approves Tofaş Takeover of Stellantis Distribution Unit
Apr 20, 2025 by
CPI
Ohio Sues United Wholesale Mortgage Over Alleged Broker Collusion
Apr 20, 2025 by
CPI
Italy Reconsiders Digital Services Tax as US Tech Pressure Mounts
Apr 20, 2025 by
CPI
Japan’s Antitrust Regulator to Warn Top Tokyo Hotels Over Pricing Information Sharing
Apr 20, 2025 by
CPI
Senate Judiciary Committee Advances Bipartisan Bills to Address Drug Pricing and Competition
Apr 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet